Our law firm is investigating Vaxart, Inc (NASDAQ: VXRT) after The New York Times reported on the company’s announcement that the vaccine it had been working on was selected to be part of the government’s Operation Warp Speed. According to the article, the company’s reality is more complex than the announcement may have stated, and company insiders saw the value of their recently acquired stock options increase dramatically as a result of the accouncement.

On this news, Vaxart stock dropped significantly. VXRT shareholders may have a claim.

Lost Money in Vaxart Stock?

You may be eligible to recover your losses. Get a free and confidential consultation.

(Please provide number of shares, purchase date, and estimated losses.)

  • This field is for validation purposes and should be left unchanged.


Vaxart Insiders Profit on COVID-19 Announcement; NY Times Says Reality is "More Complex"

On July 25, 2020, The New York Times published an article stating that after Vaxart’s surprise announcement regarding its coronavirus vaccine, company insiders saw the value of their stock options soar, and a hedge fund that partly controlled the company gained nearly $200 million in instant profits.

Vaxart had announced that the vaccine it’s been working on was selected to be part of Operation Warp Speed, a federal initiative meant to quickly develop drugs to combat COVID-19. However, according to The New York Times, the company’s reality is “more complex” than the announcement may have stated.

The article reports that, while Vaxart’s vaccine was in a trial being organized in conjunction with Operation Warp Speed, Vaxart is not one of the companies selected to receive significant funding from the operation to mass-produce vaccine doses. According to The New York Times,

Some officials at the Department of Health and Human Services have grown concerned about whether companies including Vaxart are trying to inflate their stock prices by exaggerating their roles in Warp Speed, a senior Trump administration official said. The department has relayed those concerns to the Securities and Exchange Commission, said the official, who spoke on the condition of anonymity.

On this news Vaxart stock dropped, significantly harming investors. Speak with a securities fraud lawyer to learn more about your potential claim.

Our Securities Lawyers Have a Winning Record Against Companies Like Vaxart

Our securities lawyers have recovered over a billion dollars on behalf of our clients against behemoths, such as Chase Bank, Mastercard, and Anthem Blue Cross Blue Shield. Read more about our results.

You “shouldn’t presume that powerful banks and other powerful interests can just get away with doing bad things. Good, qualified counsel that are committed to a cause can usually figure out how to prosecute such cases effectively and prevail.”

Eric Gibbs, award-winning securities attorney

Praise from the Courts

Federal judge in our AT&T class action:

“I’ve always found them to be extraordinary counsel in terms of their preparation and their professionalism.”

Federal judge in our Chase lawsuit (resulting in $100 million settlement):

They “fought tooth and nail, down to the wire” to achieve “the best settlement that they could under the circumstances.”

Read more about what judges say about us.

Michael Schrag

Michael has over 20 years of experience representing individual and small business plaintiffs against the world’s large financial institutions, including Visa, Mastercard, and Chase.

Eileen Epstein

Eileen works closely with investors in securities cases and has over a decade of experience in the legal world. She received her law degree from American University in 2005.

David Stein

David’s advocacy has generated major recoveries for consumers impacted by financial fraud. He was named to the Top 40 Under 40 by Daily Journal and a “Rising Star in Class Actions” by Law360.

Amanda Karl

Amanda is spearheading a securities lawsuit against NantHealth concerning fraudulent statements to investors about the success of its key product.